Incyte Obtains FDA Approval of Jakafi XR Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera And Graft-Versus-Host Disease; Jakafi XR Will Be Available For Pharmacy Orders by May 8

Incyte Corporation

Incyte Corporation

INCY

0.00
  • Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)
  • Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi
  • Jakafi XR will be available for pharmacy orders by May 8

Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.